West Pharmaceutical Services Inc. (NYSE: WST) reported strong financial results for Q4 2025 and the full year, with increased net sales and adjusted diluted earnings per share. The company’s Proprietary Products segment, particularly High-Value Product Components, drove growth. West Pharmaceutical anticipates continued positive momentum and sustainable growth in 2026, forecasting higher net sales and adjusted diluted EPS.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Exton-Based West Pharmaceutical Reports Higher Q4 Sales, Earnings
West Pharmaceutical Services Inc. (NYSE: WST) reported strong financial results for Q4 2025 and the full year, with increased net sales and adjusted diluted earnings per share. The company’s Proprietary Products segment, particularly High-Value Product Components, drove growth. West Pharmaceutical anticipates continued positive momentum and sustainable growth in 2026, forecasting higher net sales and adjusted diluted EPS.